Costs and absence of HCV-infected employees by disease stage

Journal of Medical Economics

Volumn 18, Issue 9, 2015, Pages 691-703

  Baran, Robert W ^a   Samp, Jennifer C ^a   Walker, David R ^a   Smeeding, James E ^b   Young, Jacob W ^c   Kleinman, Nathan L ^c   Brook, Richard A ^d  

^a ABBVIE INC   (United States)

^b President   (United States)

^c Human Capital Management Services   (United States)

^d Retrospective Analysis   (United States)

Author keywords

Absenteeism; Cirrhosis; Costs of care Healthcare expenditures; Hepatitis; Hepatocellular carcinoma; Livertransplant; Presenteeism

Indexed keywords

ABSENTEEISM; ARTICLE; CHARLSON COMORBIDITY INDEX; COMORBIDITY; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DECOMPENSATED LIVER CIRRHOSIS; DISEASE COURSE; DISEASE SEVERITY; DRUG COST; DRUG USE; FEMALE; HEALTH CARE COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; ICD-9-CM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MARRIAGE; MEDICAL DECISION MAKING; MEDICAL LEAVE; NONHUMAN; QUANTITATIVE ANALYSIS; SALARY; SEX DIFFERENCE; WORKMAN COMPENSATION; COMPLICATION; COST OF ILLNESS; ECONOMICS; FEE; HEALTH STATUS; MENTAL HEALTH; MIDDLE AGED; PRODUCTIVITY; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; SOCIOECONOMICS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

ABSENTEEISM; COMORBIDITY; COST OF ILLNESS; EFFICIENCY; FEES, PHARMACEUTICAL; FEMALE; HEALTH STATUS; HEPATITIS C; HUMANS; MALE; MENTAL HEALTH; MIDDLE AGED; MODELS, ECONOMETRIC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SOCIOECONOMIC FACTORS; TIME FACTORS;

EID: 84940366755     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2015.1045423     Document Type: Article

References (25)

1. CDC. Hepatitis C FAQs for Health Professionals. Atlanta, GA: Centers for Disease Control and Prevention. http://www.cdc.gov/hepatitis/hcv/hcvfaq.htm#-. Accessed March 6, 2015
2. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med 2014;160:293-300
3. Chak E, Talal AH, Sherman KE, et al. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver Int 2011;31:1090-101
4. Tossi M. Labor force projections to 2020: a more slowly growing workforce. Monthly Labor Review 2012;135:43-64
5. CDC. ABCs of Viral Hepatitis. Centers for Disease Control and Prevention, US Department of Health and Human Services. http://www.cdc.gov/nchhstp/newsroom/docs/ABC-Viral-Hepatitis.pdf. Accessed March 7, 2014
6. Younossi ZM, Stepanova M, Afendy M, et al. Knowledge about infection is the only predictor of treatment in patients with chronic hepatitis C. J Viral Hepat 2013;20:550-5
7. Jacobson IM, Davis GL, El-Serag H, et al. Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection. Clin Gastroenterol Hepatol 2010;8:924-33
8. Sangiovanni A, Prati GM, Fasani P, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303-10
9. Grant WC, Jhaveri RR, McHutchison JG, et al. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 2005;42:1406-13
10. Manos MM, Darbinian J, Rubin J, et al. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting. J Manag Care Pharm 2013;19:438-47
11. Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012;56:1651-60
12. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013;57:2164-70
13. Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013;37:887-94
14. Davis GL, Alter MJ, El-Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138:513-21
15. Su J, Brook RA, Kleinman NL, et al. The Impact of Hepatitis-C Viral (HCV) Infection on work absence, productivity, and healthcare benefit costs. Hepatology 2010;52:436-42
16. Brook RA, Kleinman NL, Su J, et al. Absenteeism and productivity among employees being treated for Hepatitis C. Am J Manag Care 2011;17:657-64
17. McAdam-Marx C, McGarry LJ, Hane CA, et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011;17:531-46
18. National Compensation Survey. Program perspectives on paid sick leave. Vol 2, Issue 2. Bureau of Labor Statistics, US Department of Labor; 2012. http://www.bls.gov/opub/perspectives/program-perspectives-vol2-issue2.pdf. Accessed July 19, 2012
19. InvestorGuide Staff. Understanding Disability and Long Term Care Insurance Policies. http://www.investorguide.com/igu-article-336-disabilityinsurance-understanding-disability-and-long-term-care-insurance-policies.html. Accessed January 25, 2013
20. Hunt HA. ''Is Compensation for Workplace Injuries Adequate?'' Employment Res 2002;9:1-3. http://research.upjohn.org/empl-research/vol9/iss1/1. Accessed July 19, 2012
21. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterol 2013;13:16. doi:10.1186/1471-230X-13-16
22. Mathis AS. Economic burden and current managed care challenges associated with hepatitis C. Am J Manag Care 2012;18(14 Suppl):S350-9
23. American Association For The Study of Liver Diseases (AASLD). Practice Guidelines. Alexandria, VA: AASLD. https://www.aasld.org/practiceguidelines/Pages/default.aspx. Accessed November 20, 2014
24. Muir AJ. The rapid evolution of treatment strategies for hepatitis C. Am J Gastroenterol 2014;109:628-35
25. Stepanova M, Kanwal F, El-Serag HB, et al. Insurance status and treatment candidacy of hepatitis C patients: analysis of population-based data from the United States. Hepatology 2011;53:737-45